PROCEPT BioRobotics (NASDAQ:PRCT) Shares Gap Up After Insider Buying Activity

PROCEPT BioRobotics Corporation (NASDAQ:PRCT)’s share price gapped up before the market opened on Tuesday following insider buying activity. The stock had previously closed at $25.26, but opened at $26.87. PROCEPT BioRobotics shares last traded at $25.46, with a volume of 326,976 shares traded.

Specifically, Director Antal Rohit Desai acquired 98,699 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were purchased at an average price of $24.55 per share, with a total value of $2,423,060.45. Following the completion of the purchase, the director directly owned 426,262 shares of the company’s stock, valued at $10,464,732.10. This represents a 30.13% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Antal Rohit Desai acquired 160,317 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were bought at an average price of $23.59 per share, with a total value of $3,781,878.03. Following the completion of the purchase, the director owned 327,563 shares in the company, valued at $7,727,211.17. This trade represents a 95.86% increase in their position. The disclosure for this purchase is available in the SEC filing. In other news, Director Antal Rohit Desai bought 167,246 shares of PROCEPT BioRobotics stock in a transaction that occurred on Thursday, March 5th. The stock was bought at an average cost of $25.58 per share, with a total value of $4,278,152.68. Following the acquisition, the director owned 167,246 shares of the company’s stock, valued at $4,278,152.68. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Analyst Ratings Changes

PRCT has been the topic of several analyst reports. Robert W. Baird assumed coverage on shares of PROCEPT BioRobotics in a report on Friday, March 6th. They set a “neutral” rating and a $30.00 price target on the stock. Wells Fargo & Company reduced their price objective on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating for the company in a research note on Thursday, February 26th. Morgan Stanley lowered their target price on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 2nd. Bank of America downgraded shares of PROCEPT BioRobotics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $38.00 to $20.00 in a report on Thursday, February 26th. Finally, UBS Group started coverage on PROCEPT BioRobotics in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $40.82.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed large open‑market purchases (roughly $10M+ of stock across March 5–9), increasing his stake markedly — a strong insider vote of confidence that can support the share price. Read More.
• Positive Sentiment: Research coverage was started at Robert W. Baird (coverage can increase visibility and trading interest); that may help liquidity and analyst engagement. Read More.
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold modest stakes (~6.7k and ~6.9k shares on March 6); small insider sales can be personal liquidity and are smaller in scale than the director’s purchases. Read More.
• Negative Sentiment: Multiple law firms (Glancy Prongay Wolke & Rotter, Pomerantz, Frank R. Cruz, Levi & Korsinsky and others) have announced securities‑fraud investigations into PRCT, citing prior guidance/comments on revenue and handpiece pricing — this raises litigation risk, potential disclosures or restatements, and near‑term downward pressure on sentiment. Read More.
• Negative Sentiment: Recent quarterly results (Feb. 25) missed consensus: EPS and revenue came in below expectations — a key fundamental headwind that likely prompted analyst target downgrades and is feeding the ongoing scrutiny. Read More.

PROCEPT BioRobotics Stock Performance

The firm has a market capitalization of $1.36 billion, a PE ratio of -14.13 and a beta of 1.02. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.77 and a current ratio of 6.85. The business’s fifty day simple moving average is $28.96 and its 200-day simple moving average is $32.71.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The company had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.PROCEPT BioRobotics’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.35) EPS. As a group, equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisory Services Network LLC grew its position in shares of PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock valued at $1,158,000 after purchasing an additional 250 shares in the last quarter. Vega Investment Solutions lifted its position in shares of PROCEPT BioRobotics by 52.0% in the second quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after buying an additional 265 shares in the last quarter. Frank Rimerman Advisors LLC boosted its stake in PROCEPT BioRobotics by 0.3% during the third quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company’s stock valued at $4,368,000 after buying an additional 307 shares during the last quarter. RiverPark Advisors LLC grew its holdings in PROCEPT BioRobotics by 22.5% during the 2nd quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock valued at $101,000 after buying an additional 324 shares in the last quarter. Finally, Osaic Holdings Inc. grew its holdings in PROCEPT BioRobotics by 20.3% during the 2nd quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after buying an additional 337 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.